Who
Winston Kung
Director
Company insider
Files Form 4 as: Director, Janux Therapeutics; Director, Corbus Pharmaceuticals Holdings; Chief Financial Officer, ArriVent BioPharma; COO, CFO, PMV Pharmaceuticals.
In numbers
- Trades disclosed
- 47
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $640K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 8 Dec 2020
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,500 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Sold | $16K2,026 at $7.91 | filing |
| 10 Jun 2026filed 11 Jun 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Sold | $16K2,026 at $7.91 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,300 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —3,800 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,667 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,750 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —4,800 at $0.00 | filing |
| 3 Feb 2025filed 14 Feb 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Aug 2024filed 20 Aug 2024 | CRBP Corbus Pharmaceuticals Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,566 at $0.00 | filing |
| 16 Aug 2024filed 20 Aug 2024 | CRBP Corbus Pharmaceuticals HoldingsBiotechnology | SEC FORM 4 Code A | —5,566 at $0.00 | filing |
| 26 Jun 2024filed 28 Jun 2024 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,350 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.